Covered recipient · General Payments record
BENJAMIN LOCKSHIN
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$403,106.46
489 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $315,272.00 | 111 |
| Consulting Fee | $48,744.50 | 31 |
| Travel and Lodging | $32,395.27 | 115 |
| Food and Beverage | $6,687.73 | 231 |
| Education | $6.96 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie Inc. | $117,754.72 | 127 |
| Lilly USA, LLC | $79,618.07 | 79 |
| GENZYME CORPORATION | $77,360.00 | 68 |
| Regeneron Healthcare Solutions, Inc. | $51,468.17 | 61 |
| UCB, Inc. | $42,672.13 | 44 |
| Novartis Pharmaceuticals Corporation | $23,728.11 | 41 |
| Incyte Corporation | $6,104.75 | 9 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,480.00 | 1 |
| LEO Pharma Inc. | $918.75 | 11 |
| E.R. Squibb & Sons, L.L.C. | $279.15 | 5 |
| Janssen Biotech, Inc. | $183.39 | 14 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $171.91 | 9 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $68.47 | 4 |
| PFIZER INC. | $66.30 | 4 |
| Almirall LLC | $64.06 | 3 |
| VYNE Pharmaceuticals Inc. | $57.27 | 3 |
| Galderma Laboratories, L.P. | $37.78 | 2 |
| MAYNE PHARMA INC. | $23.17 | 1 |
| DERMIRA, INC. | $19.23 | 1 |
| Sebela Pharmaceuticals Inc. | $15.55 | 1 |
| Allergan, Inc. | $15.48 | 1 |
Page 2 of 10; records 51–100 of 489 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BENJAMIN LOCKSHIN
NPI 1275523110 · CMS profile ID 239166
Allopathic & Osteopathic Physicians / Dermatology
SILVER SPRING, MD
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 10; records 51–100 of 489 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1275523110?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BENJAMIN LOCKSHIN, NPI 1275523110, CMS profile ID 239166. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 10; records 51–100 of 489 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275523110?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). BENJAMIN LOCKSHIN, NPI 1275523110, CMS profile ID 239166. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 10; records 51–100 of 489 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275523110?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- BENJAMIN LOCKSHIN, NPI 1275523110, CMS profile ID 239166, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 10; records 51–100 of 489 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1275523110?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
489 matching records · $403,106.46 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 489.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $425.46 | 11/30/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809600337 | CMS |
| Incyte Corporation | $17.92 | 11/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855647273 | CMS |
| Regeneron Healthcare Solutions, Inc. | $5,620.00 | 11/26/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809600331 | CMS |
| AbbVie Inc. | $3,500.00 | 11/24/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795366631 | CMS |
| UCB, Inc. | $710.00 | 11/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807469495 | CMS |
| UCB, Inc. | $1,065.00 | 11/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807469667 | CMS |
| UCB, Inc. | $887.50 | 11/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807469669 | CMS |
| UCB, Inc. | $710.00 | 11/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807469673 | CMS |
| UCB, Inc. | $1,180.00 | 11/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807469697 | CMS |
| AbbVie Inc. | $3,500.00 | 11/23/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795366625 | CMS |
| Regeneron Healthcare Solutions, Inc. | $146.75 | 11/23/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809600329 | CMS |
| AbbVie Inc. | $4,900.00 | 11/22/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795366619 | CMS |
| Lilly USA, LLC | $115.00 | 11/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818967089 | CMS |
| Lilly USA, LLC | $702.12 | 11/22/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818981893 | CMS |
| UCB, Inc. | $1,600.00 | 11/22/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807440203 | CMS |
| Novartis Pharmaceuticals Corporation | $5,580.00 | 11/20/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813034253 | CMS |
| AbbVie Inc. | $955.50 | 11/19/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795366613 | CMS |
| Regeneron Healthcare Solutions, Inc. | $68.75 | 11/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809600327 | CMS |
| AbbVie Inc. | $13.85 | 11/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795366589 | CMS |
| AbbVie Inc. | $442.25 | 11/18/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795366595 | CMS |
| AbbVie Inc. | $253.40 | 11/18/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795366601 | CMS |
| AbbVie Inc. | $466.41 | 11/18/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795366607 | CMS |
| Lilly USA, LLC | $2,800.00 | 11/18/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818967143 | CMS |
| Lilly USA, LLC | $2,450.00 | 11/18/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818967147 | CMS |
| Regeneron Healthcare Solutions, Inc. | $375.70 | 11/18/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809600323 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2,951.00 | 11/18/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809600325 | CMS |
| AbbVie Inc. | $113.60 | 11/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795366573 | CMS |
| AbbVie Inc. | $866.05 | 11/17/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795366579 | CMS |
| AbbVie Inc. | $182.25 | 11/17/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795366583 | CMS |
| Regeneron Healthcare Solutions, Inc. | $125.00 | 11/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809600321 | CMS |
| Regeneron Healthcare Solutions, Inc. | $16.02 | 11/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809600319 | CMS |
| AbbVie Inc. | $26.89 | 11/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795366567 | CMS |
| Regeneron Healthcare Solutions, Inc. | $11.25 | 11/15/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809600317 | CMS |
| E.R. Squibb & Sons, L.L.C. | $77.06 | 11/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783617537 | CMS |
| Lilly USA, LLC | $96.39 | 11/14/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818967871 | CMS |
| Lilly USA, LLC | $280.83 | 11/14/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818970599 | CMS |
| Lilly USA, LLC | $31.58 | 11/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818973639 | CMS |
| Lilly USA, LLC | $268.88 | 11/14/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818981889 | CMS |
| UCB, Inc. | $28.70 | 11/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807441025 | CMS |
| Regeneron Healthcare Solutions, Inc. | $23.19 | 11/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809600315 | CMS |
| Lilly USA, LLC | $42.24 | 11/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818898459 | CMS |
| Lilly USA, LLC | $26.15 | 11/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818976947 | CMS |
| GENZYME CORPORATION | $1,967.00 | 11/11/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843584095 | CMS |
| AbbVie Inc. | $11.80 | 11/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795366561 | CMS |
| AbbVie Inc. | $29.11 | 11/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795366547 | CMS |
| AbbVie Inc. | $3,500.00 | 11/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795366555 | CMS |
| Novartis Pharmaceuticals Corporation | $18.55 | 11/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813034385 | CMS |
| Novartis Pharmaceuticals Corporation | $1.73 | 11/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813034401 | CMS |
| AbbVie Inc. | $4,900.00 | 11/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795366541 | CMS |
| Incyte Corporation | $3,500.00 | 11/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835519937 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,475.44 | 8 |
| PY2025 | Principal investigator | $390,517.34 | 60 |
| PY2024 | Recipient | $10,440.71 | 7 |
| PY2024 | Principal investigator | $336,307.60 | 96 |
| PY2023 | Recipient | $6,500.91 | 11 |
| PY2023 | Principal investigator | $394,474.94 | 131 |
| PY2022 | Recipient | $11,112.63 | 26 |
| PY2022 | Principal investigator | $133,586.13 | 52 |
| PY2021 | Recipient | $6,986.32 | 16 |
| PY2021 | Principal investigator | $296,972.16 | 112 |
| PY2020 | Recipient | $11,700.12 | 17 |
| PY2020 | Principal investigator | $399,690.24 | 151 |
| PY2019 | Recipient | $36,776.58 | 17 |
| PY2019 | Principal investigator | $570,822.87 | 159 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
68 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $16,482.86 | 12/31/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228716821 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $15,000.00 | 12/26/2025 | Non-covered Recipient Entity Dermassociates | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) | No dispute reported | 06/30/2026 | 1235997720 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 12/25/2025 | Non-covered Recipient Entity DERMASSOCIATES LLC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184280318 |
| Principal investigator 1 | PFIZER INC. | $1,690.88 | 12/17/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228716823 |
| Principal investigator 1 | PFIZER INC. | $15,440.00 | 12/17/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228816598 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 12/17/2025 | Non-covered Recipient Entity DERMASSOCIATES PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184276652 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,497.00 | 12/17/2025 | Non-covered Recipient Entity DERMASSOCIATES PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184276654 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,518.00 | 12/17/2025 | Non-covered Recipient Entity DERMASSOCIATES PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184276656 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,000.00 | 12/17/2025 | Non-covered Recipient Entity DERMASSOCIATES PC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184276658 |
| Principal investigator 1 | PFIZER INC. | $12,778.46 | 12/03/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228716643 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $535.71 | 12/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184119767 |
| Principal investigator 1 | PFIZER INC. | $5,998.06 | 11/26/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228717599 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $11,500.00 | 11/24/2025 | Non-covered Recipient Entity DermAssociates, LLC, dba U.S. Dermatology Partners Rockville | Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1252797006 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,138.42 | 11/20/2025 | Non-covered Recipient Entity DERMASSOCIATES PC | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184263675 |
| Principal investigator 1 | PFIZER INC. | $2,837.71 | 11/05/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228716645 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $61.29 | 10/30/2025 | Non-covered Recipient Entity Us Dermatology Partners Rockville | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) | No dispute reported | 06/30/2026 | 1235992275 |
| Principal investigator 1 | PFIZER INC. | $2,837.71 | 10/29/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228823542 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 10/23/2025 | Non-covered Recipient Entity DERMASSOCIATES LLC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184253196 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 10/23/2025 | Non-covered Recipient Entity DERMASSOCIATES LLC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184253198 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 10/23/2025 | Non-covered Recipient Entity DERMASSOCIATES LLC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184253200 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 10/23/2025 | Non-covered Recipient Entity DERMASSOCIATES LLC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184253202 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 10/23/2025 | Non-covered Recipient Entity DERMASSOCIATES LLC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184253204 |
| Principal investigator 1 | Incyte Corporation | $284.20 | 10/22/2025 | Non-covered Recipient Entity DERMATOLOGY ASSOCIATES PC | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1240526249 |
| Principal investigator 1 | PFIZER INC. | $1,354.73 | 10/22/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228823680 |
| Principal investigator 1 | ABBVIE INC. | $1,032.90 | 10/09/2025 | Non-covered Recipient Entity DERMASSOCIATES LLC | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202514969 |
| Principal investigator 1 | PFIZER INC. | $1,482.98 | 09/26/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228833540 |
| Principal investigator 1 | PFIZER INC. | $10,957.30 | 09/12/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228833546 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 09/04/2025 | Non-covered Recipient Entity DERMASSOCIATES LLC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235119 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 09/04/2025 | Non-covered Recipient Entity DERMASSOCIATES LLC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184235121 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $292.99 | 08/29/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184119755 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $60.13 | 08/29/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184119757 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $26.73 | 08/29/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184119759 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $73.50 | 08/29/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184119761 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $2.34 | 08/29/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184119763 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $49.44 | 08/29/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184119765 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $434.60 | 08/27/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184119753 |
| Principal investigator 1 | PFIZER INC. | $9,244.15 | 08/23/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228842970 |
| Principal investigator 1 | ABBVIE INC. | $882.90 | 08/06/2025 | Non-covered Recipient Entity DERMASSOCIATES LLC | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202502689 |
| Principal investigator 1 | PFIZER INC. | $4,104.01 | 08/05/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228842947 |
| Principal investigator 1 | PFIZER INC. | $4,960.59 | 07/29/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228845685 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 07/22/2025 | Non-covered Recipient Entity DERMATOLOGY ASSOCIATES PC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240526254 |
| Principal investigator 1 | Incyte Corporation | $10,000.00 | 07/22/2025 | Non-covered Recipient Entity DERMATOLOGY ASSOCIATES PC | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240526258 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,342.00 | 07/22/2025 | Non-covered Recipient Entity DERMASSOCIATES PC | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184217791 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,198.00 | 07/22/2025 | Non-covered Recipient Entity DERMASSOCIATES PC | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184217793 |
| Principal investigator 1 | PFIZER INC. | $7,836.35 | 07/17/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228844977 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $7,500.00 | 07/09/2025 | Non-covered Recipient Entity Dermassociates | A Phase III, Randomized, Sponsor Blinded Study of Relatlimab-Nivolumab Fixed Dosed Combination versus Regorafenib or Trifluridine plus Tipiracil for Participants with Later-Lines of Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1235997718 |
| Principal investigator 1 | ABBVIE INC. | $150.00 | 07/02/2025 | Non-covered Recipient Entity DERMASSOCIATES LLC | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202496353 |
| Principal investigator 1 | PFIZER INC. | $12,813.14 | 07/02/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228845690 |
| Principal investigator 1 | Eli Lilly and Company | $21,669.00 | 07/01/2025 | Non-covered Recipient Entity DERMASSOCIATES PC | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187881112 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 06/19/2025 | Non-covered Recipient Entity DERMASSOCIATES LLC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184209418 |
| Principal investigator 1 | PFIZER INC. | $3,365.56 | 05/30/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228856943 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,425.93 | 05/27/2025 | Non-covered Recipient Entity DERMATOLOGY AND SKIN CANCER SPECIALISTS LLC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184198751 |
| Principal investigator 1 | PFIZER INC. | $8,252.15 | 05/16/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228856935 |
| Principal investigator 1 | PFIZER INC. | $7,168.77 | 05/06/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228856908 |
| Principal investigator 1 | PFIZER INC. | $7,995.65 | 04/09/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228856896 |
| Principal investigator 1 | Eli Lilly and Company | $1,084.80 | 03/25/2025 | Non-covered Recipient Entity DERMATOLOGY AND SKIN CANCER SPECIALISTS LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187882348 |
| Principal investigator 1 | Eli Lilly and Company | $24,296.15 | 03/19/2025 | Non-covered Recipient Entity DERMASSOCIATES PC | AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB | No dispute reported | 06/30/2026 | 1187880095 |
| Principal investigator 1 | PFIZER INC. | $5,100.32 | 03/06/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228861439 |
| Principal investigator 1 | PFIZER INC. | $10,748.06 | 03/04/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228861521 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 02/20/2025 | Non-covered Recipient Entity DERMASSOCIATES LLC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155094 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 02/20/2025 | Non-covered Recipient Entity DERMASSOCIATES LLC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155098 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $400.00 | 02/20/2025 | Non-covered Recipient Entity DERMASSOCIATES LLC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155102 |
| Principal investigator 1 | Eli Lilly and Company | $26,822.00 | 02/18/2025 | Non-covered Recipient Entity DERMASSOCIATES PC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187880461 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,657.75 | 02/12/2025 | Non-covered Recipient Entity Dermassociates | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1235997722 |
| Principal investigator 1 | PFIZER INC. | $22,014.59 | 02/11/2025 | Non-covered Recipient Entity DermAssociates | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228833581 |
| Principal investigator 1 | Amgen Inc. | $1,175.97 | 01/27/2025 | Non-covered Recipient Entity DERM ASSOCIATES, PC | A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) | No dispute reported | 06/30/2026 | 1246640693 |
| Principal investigator 1 | Eli Lilly and Company | $48,017.00 | 01/07/2025 | Non-covered Recipient Entity DERMASSOCIATES PC | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187880767 |
| Principal investigator 1 | ABBVIE INC. | $4,000.00 | 01/02/2025 | Non-covered Recipient Entity DERMASSOCIATES LLC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202434918 |